Pharmafile Logo

Communiqué Awards 2016: Excellence in Communication of Survey or Market Research Data

July 13, 2016 | Communiqué Awards, Lucid 

The winning programme – Treating beyond symptoms in IBD: The Steroid Assessment Tool.

Our approach to medical education is really helping to improve patient outcomes and change lives.

Inflammatory bowel disease (IBD) affects more than 250,000 patients in the UK. Treatment strategies have progressed to treating beyond the symptoms of IBD, aiming to reduce mucosal inflammation, sustain remission and prevent bowel damage. 

Steroids have a place in the treatment pathway but do not sustain remission and are associated with significant side effects.The European Crohn’s and Colitis Organisation (ECCO) defines appropriate steroid use and recommends an exit strategy for steroid-dependent patients. However, gastroenterologists are not aware that inappropriate steroid use occurs in their own clinical practice.

Using a simple digital tool, UK experts audited their own practice and were surprised to see high steroid use among their patients. The expert group became advocates for change, motivated to share their data, targeting more than 300 UK HCPs with high steroid use, which comprises approximately 22% of UK IBD clinicians. Awareness of inappropriate steroid use, and the changes driven by the self-realisation of the need to optimise steroids, have the potential to impact the care delivered to over 50,000 UK IBD patients.


This content was provided by Lucid Group Communications Limited

Company Details

 Latest Content from  Lucid Group Communications Limited 

My Lucid journey from PMW to Head of Medical

Working in Medical Communications has never been about the nine to five. Fusing science and language in the service of both clients and patients, this is typically a fast paced...

Listen, learn and lift off

In April’s PME, Danny Buckland has been talking to industry leaders about launch excellence in the featured article, Listen, learn and lift off.Buckland points out that pandemic storms have changed the...

Launch excellence

In the April edition of PME, Cheryl Harrison Doyle, Global Asset Strategy Director at Lucid Group discusses the need to take a more considered, outcomes-led approach when launching new medicines...

Meet The Lucid Group Talent Team

Meet our talent team, they're here to help and transform your career.We have some exciting roles at all levels in account management and medical writing.If you choose to take your...

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we’re excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Extraordinary lives: advancing change in rare diseases (Part 2)

In support of Rare Disease Day, we're excited to launch part 2 of our video series; Extraordinary lives: advancing change in rare diseases.Why is raising awareness of rare diseases so...

Extraordinary lives: advancing change in rare diseases (Part 1)

Rare Disease Day is all about raising awareness and generating change for the 300 million people worldwide living with a rare disease. The global rare disease community and its supporters come together on...

My Journey into MedComms #LucidLife

I began as a medical writer after almost a decade working in medical publishing as a production editor. Whilst working in publishing, I was exposed to lots of different writing...

International Women’s Day 2022 #BreakTheBias

Today is International Women’s Day. This day is about gender equality, which, to be achieved, must involve the calling out of gender bias, discrimination and stereotyping.Individually, we're all responsible for...